VascularWeb Home

• Research Initiatives Conference
• Speaker Forms
• Contact Us

Home > Medical Professionals > Research Initiatives Conference > Research Initiatives Conference

Research Initiatives In Vascular Disease Conference

2008 Joan L. and Julius H. Jacobson
Research Initiatives in Vascular Disease Conference 

Clinical Trials in Vascular Disease: Getting Answers That Matter

April 10 - 11, 2008
Renaissance Washington, DC Hotel
Washington, DC

Program Overview Learning Objectives Who Should Attend? Continuing Medical Education (CME) Credit Hotel Accommodations

Program Schedule Program Directors and Moderators Faculty Faculty Disclosure Meeting Registration Form

 

Program Overview

This program will address unanswered questions in the management of lower extremity arterial and carotid occlusive disease and how to get answers through a clinical trial.

Learning Objectives

At the end of this session, participants should be able to:

Session I:

1. Understand the present state of therapy for superficial femoral artery (SFA) and popliteal disease.
2. Evaluate the current success and failure of clinical trials in SFA and popliteal disease.
3. Determine the current clinical questions that need to be answered through clinical trials in SFA and popliteal disease.
4. Define the optimal parameters that should be applied during the development and implementation of any new clinical trial.

Session II:

1. Discuss the current and future trends in management of patients with critical limb ischemia.
2. Critically assess current studies and determine needs for future trials in patients with critical limb ischemia.

Session III:

1. Identify three potential pharmacological agents useful in limb salvage.
2. Identify two gene targets recently evaluated in the treatment of critical limb ischemia.
3. List two recent clinical trials evaluating cell therapy for limb salvage.
4. List two unconventional methods for treating critically ischemic limbs.
5. Identify two indications for primary amputation in treating patients with unreconstructable vascular disease.

Session IV:

1. Understand the distinct interests of the NIH, FDA, CMS and VA with regard to best available data to guide peripheral arterial disease management.
2. Understand how these distinct interests affect their willingness to support the acquisition of such data.

Session V:

1. Review pertinent clinical evidence of carotid artery stenting (CAS). 
2. Determine appropriate therapeutic options for patients with carotid artery stenosis.
3. Determine appropriate endpoints for upcoming CAS trials

Session VI:

1. Understand the factors contributing to the slower than anticipated growth of carotid stenting as they are related to: (a) patient selection, (b) lesion selection, (c) current technology shortcomings, and (d) operator training and economic considerations.
2. Review the progress made on the technology, techniques, and training related to carotid stenting.
3. Apply the results of clinical trials to the management of their patients.

Who Should Attend?

The Research Initiatives in Vascular Disease Conference brings together vascular surgeons, vascular medicine physicians, vascular interventionalists, cardiologists, basic scientists, and clinical scientists from other disciplines to facilitate research in vascular disease through an exchange of information and ideas. 

Continuing Medical Education (CME) Credit

The Society for Vascular Surgery (SVS) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The SVS designates this educational activity for a maximum of 9.75 AMA PRA Category 1 Credits™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

Hotel Accommodations

Renaissance Washington, DC Hotel
999 9th Street, NW
Washington, DC 20001
Hotel Phone: 202-898-9000
Reservations: 202-962-4471
International Reservations: 801-832-4532
Online Reservation: http://marriott.com/wasrb?groupCode=svssvsa&app=resvlink
Room Rate: $229 single/double
Note:  Cutoff has been extended!  Please call asap to reserve a room as the room block is almost full! 

Please call 800-258-7188 or email education@vascularsociety.org if you have questions.

*Program Schedule

Thursday, April 10, 2008
7:30 am	Continental Breakfast/Registration
8:15 am	Introductory Remarks Larry W. Kraiss, MD
8:25 am	The William J. von Liebig Award (Lifeline KO8) Winners Alan Dardik, MD, PhD Yale University School of Medicine, New Haven, CT Melina Kibbe, MD Northwestern University, Chicago, IL
8:45 am	Session I – PAD: Claudication & Interventions on the Superficial Femoral and Popliteal Arteries  Moderators: Mark G. Davies, MD, PhD and Gregory L. Moneta, MD
	8:45 Current Situation in the Field Mark G. Davies, MD, PhD 9:05   Disease Classification and Appropriate Functional Outcomes for Clinical Trials Mary M. McDermott, MD    9:25   Interventional Therapy vs. Best Medical Therapy Timothy P. Murphy, MD     9:40   What is the Best Global Strategy for Claudication? Gregory L. Moneta, MD 10:00  Panel Discussion
10:15 am	Coffee Break
10:45 am	Session II – PAD: Critical Limb Ischemia (CLI) & Interventions on the Infrapopliteal Arteries Moderators: Alan Dardik, MD, PhD and Michael S. Conte, MD
	10:45   The Clinical Research Challenges of the CLI Population Mark R. Nehler, MD  11:05   What Are the Functional Outcomes of Interest in Patients With CLI? Gregory J. Landry, MD 11:25   Atherectomy and Other Devices; What is Wrong With Registry Data and Should They Be Compared With PTA or Open Surgery? Sean P. Lyden, MD 11:40   Results of Surgical Intervention for CLI: Defining Performance Goals for Endovascular Approaches Michael S. Conte, MD 12:00 Panel Discussion
12:15 pm	Lunch
1:15 pm	Session III – PAD: Rescue Therapy for Unreconstructible CLI Moderators: Paul J. DiMuzio, MD and Jeffrey Lawson, MD
	1:15 Is There a Role for Existing Pharmacologic Treatments? Daniel Duprez, MD, PhD, FAHA, FACC, FESC 1:30   Does Gene Therapy Have Anything to Offer? Brian Annex, MD    1:45   Can Cell-Based Treatments Save Limbs? Doug W. Losordo, MD      2:00  Unconventional Treatments for CLI Peter F. Lawrence, MD 2:15  Last But Not Least: The Role of Primary Amputation in the Treatment of CLI John V. White, MD 2:30  Panel Discussion
2:45 pm	Coffee Break
3:15 pm	Session IV – PAD: Regulatory & Economic Considerations in PAD Therapy Moderators: Larry W. Kraiss, MD and Robert M. Zwolak, MD, PhD
	3:15   Introduction and Overview Robert M. Zwolak, MD, PhD   3:30   The NIH Perspective David J. Gordon, MD, PhD    3:45   The FDA Perspective Allison M. Kumar      4:00   The CMS Perspective Steve E. Phurrough, MD, MPA 4:15  The VA Perspective Grant D. Huang, MPH, PhD 4:30  Panel Discussion
4:45 pm	Adjourn
5:00 pm	Q&A Session for Trainees
6:00 pm	Welcome Reception
Friday, April 11, 2008
7:30 am	Continental Breakfast/Registration
8:30 am	Session V – Carotid Disease: Current Status of Completed & Ongoing Trials of CEA vs. CAS  Moderators: Eva M. Rzucidlo, MD and Jon S. Matsumura, MD
	8:30 Summary of US IDE/PMS Registry Data: What are the Appropriate Endpoints to Make Appropriate Conclusions? Alan B. Lumsden, MD   8:45 Design and Lead-In Results of CREST: Will There Be Questions Left Unanswered?   Thomas G. Brott, MD    9:00   Review of Stopped Trials: SPACE and EVA 3-S. Did We Learn Anything?    Eva M. Rzucidlo, MD     9:15   Review of Ongoing Trials Focused on the Asymptomatic Standard Risk Population:  ACT 1 and ACT 2 Jon S. Matsumura, MD 9:30  Perspective of FDA on CAS?  Are the Current Endpoints Adequate?  What Types of Trials Will Be Needed?  Bram D. Zuckerman, MD, FACC 9:45  Panel Discussion
10:00 am	Coffee Break
10:15 am	Session VI – Carotid Disease Moderators: Iraklis I. Pipinos, MD and Peter L. Faries, MD
	10:15   Carotid Stenting in 2007: Remaining Obstacles Iraklis I. Pipinos, MD  10:30   Do We Really Know Which Patients Can Be Optimally Managed With CAS versus Endarterectomy? Gary S. Roubin, MD, PhD 10:45   Has Carotid Stenting Reached a Technological Plateau?  L. Nelson Hopkins, MD  11:00   Are We Ready to Chose Carotid Treatment Based on Plaque Composition and Evaluate Outcomes Based on DW-MRI Rather Than Neurological Evaluation? Brian G. DeRubertis, MD 11:15  Obstacles to Carotid Stenting Dissemination: Operator Training and Economic Considerations Michael B. Silva, Jr., MD    11:30  Panel Discussion
11:45 am	Adjourn

 

*Program subject to change

Program Directors and Moderators

Program Directors

Larry W. Kraiss, MD, Chair, Research and Education Committee
University of Utah, Salt Lake City, UT

Michael S. Conte, MD, Chair, Clinical Research Committee
Brigham & Women's Hospital, Boston, MA

Moderators

Alan Dardik, MD, PhD
Yale University School of Medicine, New Haven, CT

Mark G. Davies, MD, PhD
University of Rochester Med Center, Rochester, NY

Paul J. DiMuzio, MD
Jefferson Hospital, Philadelphia, PA

Peter L. Faries, MD
Mount Sinai School of Medicine, New York, NY

Jeffrey Lawson, MD
Duke University Medical Center, Durham, NC

Jon S. Matsumura, MD
Northwestern Memorial Faculty Foundation, Chicago, IL

Gregory L. Moneta, MD
Oregon Health & Sciences University, Portland, OR

Iraklis I. Pipinos, MD
University of Nebraska Medical Center, Omaha, NE

Eva M. Rzucidlo, MD
Dartmouth Hitchcock Medical Center, Lebanon, NH

Robert M. Zwolak, MD, PhD
Dartmouth Hitchcock Medical Center, Lebanon, NH

Faculty

Brian H. Annex, MD
Duke Cardiology at the Durham VA Medical Center, Durham, NC

Thomas G. Brott, MD
Mayo Clinic Jacksonville, Jacksonville, FL

Brian G. DeRubertis, MD
UCLA School of Medicine, Los Angeles, CA

Daniel Duprez, MD, PhD, FAHA, FACC, FESC
University of Minnesota, Minneapolis, MN

David J. Gordon, MD, PhD
National Institutes of Health, Bethesda, MD

L. Nelson Hopkins, MD
University at Buffalo, The State University of New York, Buffalo, NY

Grant D. Huang, MPH, PhD
VA Cooperative Studies Program, Washington, DC

Allison M. Kumar
US Food and Drug Administration, Rockville, MD

Gregory J. Landry, MD
Oregon Health & Science University, Portland, OR

Peter F. Lawrence, MD
UCLA Medical Center, Los Angeles, CA

Doug W. Losordo, MD
Northwestern University Feinberg School of Medicine, Chicago, IL

Alan B. Lumsden, MD,
Methodist DeBakey Heart Center, Houston, TX

Sean P. Lyden, MD
Cleveland Clinic Foundation, Cleveland, OH

Mary M. McDermott, MD
Northwestern University’s Feinberg School of Medicine, Chicago, IL

Timothy P. Murphy, MD
Rhode Island Hospital, Providence, RI

Mark R. Nehler, MD
University of Colorado Health Sciences Center, Denver, CO

Steve E. Phurrough, MD, MPA
Centers for Medicare & Medicaid Services, Baltimore, MD

Gary S. Roubin, MD, PhD
Lenox Hill Hospital, New York, NY

Michael B. Silva, Jr., MD
University of Texas Medical Branch, Galveston, TX

John V. White, MD
Advocate-Lutheran General Hospital, Park Ridge, IL

Bram D. Zuckerman, MD, FACC
US Food and Drug Administration, Rockville, MD

Faculty Disclosure

Disclosure statements have been requested from the faculty and will be made available at the conference. Faculty presenters are also expected to disclose to participants any discussions of off-label and/or investigational uses of pharmaceutical products and/or medical devices during their presentations.